After finishing at $65.24 in the prior trading day, Exact Sciences Corp. (NASDAQ: EXAS) closed at $66.88, up 2.51%. In other words, the price has increased by $+1.64 from its previous closing price. On the day, 1710299 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of EXAS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 380.23. For the most recent quarter (mrq), Quick Ratio is recorded 2.07 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on December 13, 2023, with a $95 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 01 ’24 when Conroy Kevin T sold 8,271 shares for $59.32 per share. The transaction valued at 490,636 led to the insider holds 1,299,496 shares of the business.
LEVANGIE DANIEL J sold 5,000 shares of EXAS for $287,500 on Mar 01 ’24. The Director now owns 22,975 shares after completing the transaction at $57.50 per share. On Mar 01 ’24, another insider, Cunningham Everett, who serves as the Chief Commercial Officer of the company, sold 2,412 shares for $59.32 each. As a result, the insider received 143,080 and left with 46,179 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 12.14B and an Enterprise Value of 13.92B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.86 while its Price-to-Book (P/B) ratio in mrq is 3.86. Its current Enterprise Value per Revenue stands at 5.57 whereas that against EBITDA is 475.41.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $100.77, while it has fallen to a 52-week low of $56.05. The 50-Day Moving Average of the stock is 61.79, while the 200-Day Moving Average is calculated to be 72.86.
Shares Statistics:
The stock has traded on average 1.94M shares per day over the past 3-months and 2.08M shares per day over the last 10 days, according to various share statistics. A total of 181.36M shares are outstanding, with a floating share count of 179.64M. Insiders hold about 1.04% of the company’s shares, while institutions hold 90.12% stake in the company. Shares short for EXAS as of Feb 29, 2024 were 7.04M with a Short Ratio of 3.36, compared to 7.29M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.88% and a Short% of Float of 3.91%.
Earnings Estimates
Its stock is currently analyzed by 15 different market analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.63, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.09 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.31 and -$1.29 for the fiscal current year, implying an average EPS of -$0.83. EPS for the following year is $0.07, with 16 analysts recommending between $0.81 and -$0.64.
Revenue Estimates
20 analysts predict $628.92M in revenue for the current quarter. It ranges from a high estimate of $682M to a low estimate of $619.99M. As of the current estimate, Exact Sciences Corp.’s year-ago sales were $602.45M, an estimated increase of 4.40% from the year-ago figure. For the next quarter, 20 analysts are estimating revenue of $700.17M, an increase of 12.60% over than the figure of $4.40% in the same quarter last year. There is a high estimate of $721.08M for the next quarter, whereas the lowest estimate is $682M.
A total of 22 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $2.87B, while the lowest revenue estimate was $2.82B, resulting in an average revenue estimate of $2.83B. In the same quarter a year ago, actual revenue was $2.5B, up 13.30% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $3.23B in the next fiscal year. The high estimate is $3.36B and the low estimate is $3.17B. The average revenue growth estimate for next year is up 14.10% from the average revenue estimate for this year.
